Cas9 Stable Cell Line - BEAS-2B

The Cas9-stable cell line BEAS-2B is a genetically engineered cell line derived from BEAS-2B human bronchial epithelial cells. BEAS-2B cells are derived from normal human bronchial epithelium and immortalized through transformation with adenovirus 12-SV40 hybrid virus, making them an important model for respiratory system research. In this stable cell line, the CRISPR-associated protein 9 (Cas9) nuclease is constitutively expressed under the regulation of a strong promoter, enabling highly efficient and targeted genome editing. Cas9 integration into the BEAS-2B genome ensures the stability of Cas9 protein expression during cell passaging, eliminating the need for repeated transfection. Its epithelial origin and relevance to lung biology make it particularly suitable for research involving airway diseases, toxicology, and the functional analysis of genes in the human respiratory system.

The Cas9-stable cell line BEAS-2B is primarily used for high-throughput CRISPR screening to identify gene functions in the respiratory pathway, enabling researchers to knock out specific genes associated with lung cancer, asthma, or chronic obstructive pulmonary disease (COPD) by introducing guide RNA (gRNA). This accelerates the validation of drug targets because genes associated with disease mechanisms can be systematically disrupted, allowing for the assessment of phenotypic effects and therapeutic vulnerabilities. In toxicology, this cell line can be used to study environmental pollutants (such as cigarette smoke or nanoparticles) by editing genes involved in oxidative stress or inflammatory responses. Furthermore, it supports the construction of homologous disease models—such as introducing oncogenic mutations to mimic lung cancer development—for preclinical drug testing. Beyond basic research, this cell line also plays a crucial role in the development of gene therapies, the optimization of CRISPR delivery methods, and the study of host-pathogen interactions in respiratory infections.